Sustained virological response in HCV patients treated with daclatasvir plus sofosbuvir, with or without ribavirin: a multicenter, field-practice experience

被引：0
|
作者：
Sacco, R. [1 ]
Salomoni, E. [2 ]
Parodi, S. [1 ]
Gianni, E. [3 ]
Gragnani, L. [3 ]
Andreotti, G. [4 ]
Brunetto, M. R. [5 ]
Zignego, A. L. [3 ]
Gattai, R. [5 ]
Vivaldi, I. [6 ]
De Luca, A. [7 ]
Bartolozzi, D. [2 ]
Cinelli, R. [6 ]
Pozzi, M. [2 ]
Coco, B. [5 ]
Tapete, G. [1 ]
Forte, P. [8 ]
Puntili, R. [8 ]
Ricciardi, L. [9 ]
Sani, S. [6 ]
Luchi, S. [9 ]
Valoriani, B. [7 ]
Riccardi, M. P. [4 ]
Nencioni, C. [4 ]
Aquilini, D. [10 ]
Nerli, A. [10 ]
Esperti, F. [11 ]
Mazzotta, F. [11 ]
Bresci, G. [1 ]
Colombatto, P. [5 ]
机构：
[1] Azienda Osped Univ Pisana, UO Gastroenterol & Malattie Ricambio, Pisa, Italy
[2] AOU Careggi, Malattie Infett & Trop, Florence, Italy
[3] AOU Careggi, Ctr MASVE Med Sperimentale & Clin, Florence, Italy
[4] Osped Misericordia, Malattie Infett, Grosseto, Italy
[5] Azienda Osped Univ Pisana, UO Epatol, Pisa, Italy
[6] Spedali Riuniti Livorno, Malattie Infett, Livorno, Italy
[7] Azienda Osped Univ Senese, Malattie Infett, Siena, Italy
[8] AOU Careggi, Gastroenterol 2, Florence, Italy
[9] Osped San Luca, Malattie Infett & Epatol, Lucca, Italy
[10] Nuovo Osped Prato, Malattie Infett, Prato, Italy
[11] Osped S Jacopo, Malattie Infett, Pistoia, Italy
来源：
JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(17)31958-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-264
引用
收藏
页码：S734 / S734
页数：1
相关论文
共 50 条
  • [31] Effect of sustained virological response to interferon plus ribavirin on the incidence of hepatocellular carcinoma in HCV cirrhotic patients.
    Cheinquer, H
    Cheinquer, N
    Coelho-Borges, S
    Juruena, CS
    Peres, DS
    Wolff, F
    HEPATOLOGY, 2004, 40 (04) : 323A - 323A
  • [32] Sofosbuvir plus ribavirin and sofosbuvir plus daclatasvir-based regimens are suboptimal in genotype 2 patients: real-life experience
    Hezode, C.
    De Ledinghen, V.
    Haour, G.
    Bronowicki, J. -P.
    Zoulim, F.
    Larrey, D.
    Sophie, M.
    Albert, T.
    Patrick, M.
    Samuel, D.
    Chazouilleres, O.
    Stephane, C.
    Celine, D.
    Helene, F.
    Pawlotsky, J. -M.
    Fabrice, C.
    Stanislas, P.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S264 - S264
  • [33] Real life experience with Sofosbuvir plus Daclatasvir With or Without Ribavirin for Treatment of Chronic hepatitis C Genotype 4 Patients.
    Shiha, Gamal
    Soliman, Reham
    Elbasiony, Mohamed
    Hassan, Ayman
    Mikhail, Nabiel
    HEPATOLOGY, 2017, 66 : 835A - 835A
  • [34] Real World Outcomes of DAA Therapy With Sofosbuvir and Daclatasvir plus Ribavirin in HCV GT 3 Patients in Pakistan
    Choudhry, Asad
    Tariq, Umer
    Khalid, Ayesha
    Arif, Rabeeya
    Choudhry, Arham
    Ali, Bushra
    Nawaz, Arif
    Nawaz, Hesham
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S531 - S532
  • [35] High sustained virologic response rates in hepatitis C virus genotype 3 patients with and without cirrhosis treated with daclatasvir/sofosbuvir or velpatasvir/sofosbuvir ± ribavirin according to baseline resistance analysis
    Vermehren, J.
    Dietz, J.
    Peiffer, K. -H.
    Weiler, N.
    Muecke, V.
    Dultz, G.
    Welsch, C.
    Zeuzem, S.
    Welzel, T. M.
    Sarrazin, C.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S83 - S83
  • [36] Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
    Noha Anwar Hassuna
    Aya Nabil Gamil
    Mahmoud Shokry Mahmoud
    Wafaa Khairy Mohamed
    Rasha Khairy
    BMC Gastroenterology, 22
  • [37] Daclatasvir plus Sofosbuvir ± Ribavirin in Liver Transplant Recipients with HCV Recurrence: Interim Results of a European Multicenter Compassionate Use Program
    Herzer, Kerstin
    Welzel, Tania
    Ferenci, Peter
    Petersen, Joerg
    Gschwantler, Michael
    Cornberg, Markus
    Berg, Thomas
    Spengler, Ulrich
    Weiland, Ola
    Van der Valk, Marc
    Klinker, Hartwig
    Rockstroh, Juergen
    Schott, Eckart
    Peck-Radosavljevic, Markus
    Zhao, Yue
    Exposito, Maria-Jesus Jimenez
    Zeuzem, Stefan
    TRANSPLANTATION, 2016, 100 : S181 - S181
  • [38] Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a multicenter European compassionate use program
    Welzel, Tania M.
    Petersen, Joerg
    Ferenci, Peter
    Gschwantler, Michael
    Herzer, Kerstin
    Cornberg, Markus
    Schott, Eckart
    Berg, Thomas
    Spengler, Ulrich
    Weiland, Ola
    van der Valk, Marc
    Geier, Andreas
    Rockstroh, Juergen K.
    Peck-Radosavljevic, Markus
    Zhao, Yue
    Exposito, Maria Jesus Jimenez
    Zeuzem, Stefan
    HEPATOLOGY, 2015, 62 : 225A - 226A
  • [39] DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN FOR TREATMENT OF CHRONIC HCV INFECTION IN PATIENTS WITH ADVANCED LIVER DISEASE: RESULTS OF A EUROPEAN COMPASSIONATE USE PROGRAM
    Welzel, T.
    Petersen, J.
    Herzer, K.
    Ferenci, P.
    Gschwantler, M.
    Cornberg, M.
    Ingiliz, P.
    Berg, T.
    Spengler, U.
    Weiland, O.
    van der Valk, M.
    Klinker, H.
    Rockstroh, J.
    Peck-Radosavljevic, M.
    Zhao, Y.
    Jimenez-Exposito, M. J.
    Zeuzem, S.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S825 - S825
  • [40] The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
    Han, Sung Yong
    Woo, Hyun Young
    Heo, Jeong
    Park, Sang Gyu
    Pyeon, Sung Ik
    Park, Young Joo
    Kim, Dong Uk
    Kim, Gwang Ha
    Kim, Hyung Hoi
    Song, Geun Am
    Cho, Mong
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2021, 36 (03): : 544 - +
12345